https://www.newswire.ca/news-releases/kronos-bio-and-invivoscribe-partner-on-companion-diagnostic-for-use-with-entospletinib-kronos-bio-s-investigational-compound-being-developed-for-patients-with-aml-829799174.html
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos...
/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...